Arise logo

ARISE-HEE: Australasian Resuscitation In Sepsis Evaluation - Health Economic Evaluation: An economic evaluation of resuscitation in sepsis – a cost-effectiveness analysis alongside the ARISE-RCT.

The study involves conducting a cost-effectiveness and cost-utility analysis, from a healthcare perspective, of Early Goal Directed Therapy (EGDT) compared with standard care for patients with severe sepsis presenting to the Emergency Departments (ED) of Australian hospitals. We will use an analytic timeframe of one year to compare the cost per life year gained and the cost per quality adjusted life year (QALY) gained from the alternative treatments. A representative subgroup of 200 patients (100 EGDT, 100 standard care) from the ARISE-RCT will form the group of patients who contribute cost data and all patients will contribute quality of life data for the economic evaluation.

Patients participating will be sent the EQ-5D, the Medical Outcomes Study Short Form 36 (SF-36) questionnaire and the Assessment of Quality of Life (AQoL) instrument for completion at six and twelve months after being enrolled in the ARISE-RCT.

Goal: The aim of the study is to determine the cost-effectiveness and cost-utility of protocolised resuscitation compared to usual care in patients presenting to Australian Emergency Departments with severe sepsis.

Study Progress: Patient recruitment was completed in April 2014 and the final Quality of Life (QoL) assessments will be completed in April 2015. The cost-effectiveness analysis is expected to be completed in late 2015.

Photo of Lisa Higgins

Collaboration: The ARISE-HEE is endorsed by the ANZICS-CTG.

Funding:The ARISE-HEE is funded by the Intensive Care Foundation (ICF).

Contact: For further information about this study, please contact Lisa Higgins at the ANZIC-RC by email.